A Phase II-III Trial Assessing the Efficacy and Safety of Three Doses of the ALK HDM Tablet in House Dust Mite Allergic Patients
Phase of Trial: Phase II/III
Latest Information Update: 01 Feb 2015
At a glance
- Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
- Indications Allergic asthma; Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors ALK-Abello
- 02 May 2014 Results published in the Journal of Allergy and Clinical Immunology.
- 16 Aug 2010 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
- 16 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History